Market closed

Pyxis Oncology/$PYXS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Pyxis Oncology

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Ticker

$PYXS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

Website

www.pyxisoncology.com

Pyxis Oncology Metrics

BasicAdvanced

$86M

-

-$1.06

1.28 -

Price and volume

Market cap

$86M

Beta

1.28

52-week high

$6.85

52-week low

$1.42

Average daily volume

1.1M

Financial strength

Current ratio

7.326

Quick ratio

7.127

Long term debt to equity

12.459

Total debt to equity

13.365

Management effectiveness

Return on assets (TTM)

-21.06%

Return on equity (TTM)

-39.34%

Valuation

Price to revenue (TTM)

4.839

Price to book

0.56

Price to tangible book (TTM)

0.66

Price to free cash flow (TTM)

-1.45

Growth

Earnings per share change (TTM)

-57.97%

3-year earnings per share growth (CAGR)

-71.48%

What the Analysts think about Pyxis Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Pyxis Oncology stock.

Pyxis Oncology Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Pyxis Oncology Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Pyxis Oncology News

AllArticlesVideos

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

GlobeNewsWire·4 weeks ago

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Seeking Alpha·1 month ago

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Benzinga·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PYXS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Pyxis Oncology stock?

Pyxis Oncology (PYXS) has a market cap of $86M as of January 15, 2025.

What is the P/E ratio for Pyxis Oncology stock?

The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of January 15, 2025.

Does Pyxis Oncology stock pay dividends?

No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Pyxis Oncology dividend payment date?

Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Pyxis Oncology?

Pyxis Oncology (PYXS) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.